Research programme: LFA-1 inhibitors - Actinobac Biomed

Drug Profile

Research programme: LFA-1 inhibitors - Actinobac Biomed

Alternative Names: Leukocyte function antigen-1 (LFA-1) antagonist - Actinobac Biomed; Leukothera

Latest Information Update: 03 Apr 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Medicine & Dentistry of New Jersey
  • Developer Actinobac Biomed
  • Class Biological toxins
  • Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Haematological malignancies; HIV infections; Psoriasis

Most Recent Events

  • 28 Mar 2013 Leukothera® is still in preclinical development for Haematological malignancies in US
  • 27 Jun 2011 Interim pharmacodynamics data from a preclinical trial in Haematological malignancies released by Actinobac
  • 16 Jun 2011 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top